Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1972 1
1986 1
1987 1
1990 4
1993 1
1994 3
1995 1
2000 1
2002 2
2003 3
2004 6
2005 7
2006 7
2007 10
2008 6
2009 7
2010 7
2011 5
2012 8
2013 8
2014 6
2015 11
2016 16
2017 3
2018 6
2019 11
2020 4
2021 8
2022 5
Text availability
Article attribute
Article type
Publication date

Search Results

142 results
Results by year
Filters applied: . Clear all
Page 1
CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients.
Turtle CJ, Hanafi LA, Berger C, Gooley TA, Cherian S, Hudecek M, Sommermeyer D, Melville K, Pender B, Budiarto TM, Robinson E, Steevens NN, Chaney C, Soma L, Chen X, Yeung C, Wood B, Li D, Cao J, Heimfeld S, Jensen MC, Riddell SR, Maloney DG. Turtle CJ, et al. Among authors: jensen mc. J Clin Invest. 2016 Jun 1;126(6):2123-38. doi: 10.1172/JCI85309. Epub 2016 Apr 25. J Clin Invest. 2016. PMID: 27111235 Free PMC article. Clinical Trial.
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy.
Brown CE, Alizadeh D, Starr R, Weng L, Wagner JR, Naranjo A, Ostberg JR, Blanchard MS, Kilpatrick J, Simpson J, Kurien A, Priceman SJ, Wang X, Harshbarger TL, D'Apuzzo M, Ressler JA, Jensen MC, Barish ME, Chen M, Portnow J, Forman SJ, Badie B. Brown CE, et al. Among authors: jensen mc. N Engl J Med. 2016 Dec 29;375(26):2561-9. doi: 10.1056/NEJMoa1610497. N Engl J Med. 2016. PMID: 28029927 Free PMC article. Clinical Trial.
CD19 CAR T cell product and disease attributes predict leukemia remission durability.
Finney OC, Brakke HM, Rawlings-Rhea S, Hicks R, Doolittle D, Lopez M, Futrell RB, Orentas RJ, Li D, Gardner RA, Jensen MC. Finney OC, et al. Among authors: jensen mc. J Clin Invest. 2019 Mar 12;129(5):2123-2132. doi: 10.1172/JCI125423. Print 2019 May 1. J Clin Invest. 2019. PMID: 30860496 Free PMC article. Clinical Trial.
Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis.
Vitanza NA, Johnson AJ, Wilson AL, Brown C, Yokoyama JK, Künkele A, Chang CA, Rawlings-Rhea S, Huang W, Seidel K, Albert CM, Pinto N, Gust J, Finn LS, Ojemann JG, Wright J, Orentas RJ, Baldwin M, Gardner RA, Jensen MC, Park JR. Vitanza NA, et al. Among authors: jensen mc. Nat Med. 2021 Sep;27(9):1544-1552. doi: 10.1038/s41591-021-01404-8. Epub 2021 Jul 12. Nat Med. 2021. PMID: 34253928 Clinical Trial.
Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults.
Gardner RA, Finney O, Annesley C, Brakke H, Summers C, Leger K, Bleakley M, Brown C, Mgebroff S, Kelly-Spratt KS, Hoglund V, Lindgren C, Oron AP, Li D, Riddell SR, Park JR, Jensen MC. Gardner RA, et al. Among authors: jensen mc. Blood. 2017 Jun 22;129(25):3322-3331. doi: 10.1182/blood-2017-02-769208. Epub 2017 Apr 13. Blood. 2017. PMID: 28408462 Free PMC article. Clinical Trial.
142 results